As of close of business last night, Denali Therapeutics Inc’s stock clocked out at $19.87, up 1.27% from its previous closing price of $19.62. In other words, the price has increased by $+0.25 from its previous closing price. On the day, 932345 shares were traded. DNLI stock price reached its highest trading level at $19.96 during the session, while it also had its lowest trading level at $19.35.
Ratios:
To gain a deeper understanding of DNLI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.65 and its Current Ratio is at 13.65. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on December 13, 2023, initiated with a Buy rating and assigned the stock a target price of $32.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 15 ’24 when SATO VICKI L sold 1,666 shares for $20.10 per share. The transaction valued at 33,487 led to the insider holds 119,709 shares of the business.
SATO VICKI L sold 1,666 shares of DNLI for $30,604 on Feb 15 ’24. The Director now owns 121,375 shares after completing the transaction at $18.37 per share. On Feb 14 ’24, another insider, Schuth Alexander O., who serves as the COFO and Secretary of the company, sold 20,128 shares for $17.66 each. As a result, the insider received 355,460 and left with 187,341 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 2.73B and an Enterprise Value of 1.75B. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.37 while its Price-to-Book (P/B) ratio in mrq is 2.67. Its current Enterprise Value per Revenue stands at 5.29 whereas that against EBITDA is -9.71.
Stock Price History:
Over the past 52 weeks, DNLI has reached a high of $33.31, while it has fallen to a 52-week low of $15.45. The 50-Day Moving Average of the stock is 18.53, while the 200-Day Moving Average is calculated to be 22.11.
Shares Statistics:
It appears that DNLI traded 1.18M shares on average per day over the past three months and 1.16M shares per day over the past ten days. A total of 138.39M shares are outstanding, with a floating share count of 111.97M. Insiders hold about 19.54% of the company’s shares, while institutions hold 78.36% stake in the company. Shares short for DNLI as of Feb 29, 2024 were 8.87M with a Short Ratio of 7.52, compared to 9.84M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.37% and a Short% of Float of 7.55%.
Earnings Estimates
As of right now, 14 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.71 for the current quarter, with a high estimate of -$0.53 and a low estimate of -$0.86, while EPS last year was -$0.8. The consensus estimate for the next quarter is -$0.68, with high estimates of -$0.51 and low estimates of -$0.86.
Analysts are recommending an EPS of between -$1.12 and -$3.42 for the fiscal current year, implying an average EPS of -$2.67. EPS for the following year is -$2.69, with 13 analysts recommending between -$1 and -$3.8.
